Drug Search Results
More Filters [+]

Nonacog alfa

Alternative Names: nonacog alfa
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: FIX Analogue

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Colombia | Croatia | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Indonesia | Italy | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Spain | Taiwan | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nonacog alfa

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hemophilia B|Hemophilia A

Phase 2: Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FMTN-II-GIST

P2

Not yet recruiting

Multiple Myeloma

2022-08-01

2020-004430-38

P4

Active, not recruiting

Hemophilia B

2021-03-19

B1821059

P4

Completed

Hemophilia A|Hemophilia B

2020-09-24

2014-004156-65

P3

Active, not recruiting

Hemophilia B

2019-06-06

Recent News Events